Biologic therapies for autoimmune deseases;Intérêt des thérapies biologiques dans les maladies auto-immunes

Medecine et Hygiene

Volumn 62, Issue 2471, 2004, Pages 443-449

  Ferrari Lacraz, Sylvie ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETA1A INTERFERON; CYTOKINE; CYTOKINE RECEPTOR; EFALIZUMAB; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERFERON BETA SERINE; INTERLEUKIN 1; MONOCLONAL ANTIBODY; NATALIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; CROHN DISEASE; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; JUVENILE RHEUMATOID ARTHRITIS; NONHODGKIN LYMPHOMA; PSORIASIS; REGULATORY MECHANISM; REVIEW; RHEUMATIC FEVER; SCLEROSIS;

EID: 1542328217     PISSN: 00256749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001; 345: 340-50.
2. Liblau RS, Wong FS, Mars LT, Santamaria P. Autoreactive CD8 T cells in organ-specific autoimmunity: Emergency targets for therapeutic intervention. Immunity 2002; 17: 1-6.
3. Falcone M, Sarvetnick N. Cytokines that relate autoimmune responses. Curr Opin Immunol 1999; 11: 670-6.
4. Ermann J, Fathman CG. Autoimmune diseases, genes, bugs and failed regulation. Nat Immunol 2001; 2: 802-19.
5. Chu CQ, Field M, Feldmann M, Maini RN. Localization of tumor necrosis facteur-α in synovial tissues and at the cartilage-pannus junction in patients with rhumatoïde arthritis. Arthritis Rheum 1991; 34: 1125-32.
6. Cenci S, Weitzmann MN, Foggia C, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. J Clin Invest 1993; 106: 1229-37.
7. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991; 174: 1483-9.
8. Feldmann M, Elliot M, Woody J, Maini R. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Advances Immunol 1997; 64: 283-350.
9. Van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumor necrosis factor alpha monoclonal antibody adalimumab 8D2E7) in DMARD refractory patients with rheumatoid arthritis: A 12 week, phase II study. Ann Rheum Dis 2003; 62: 1168-77.
10. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586-93.
11. Lipsky PE, Desiree MFM, van Der Heijde MD, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
12. Lovell DJ, Giannini EH, Reiff A, et al. Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenil rheumatoid arthritis. N Engl J Med 2000; 342: 763-9.
13. Lovell DJ, Giannini EH, Reiff A, et al. Pediatric Rheumatology Collaborative Study Group. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003; 48: 218-26.
14. Lahdenne P, Vahasalo P, Honkanen V. Infiximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: An open label study. Ann Rheum Dis 2003; 62: 245-7.
15. Gerloni V, Lurati A, Gattinara M, et al. Efficacy of infusions of an antitumor necrosis factor a antibody (infliximab) in persistently active refractory juvenile idiopathic arthritis. Results of a two years open label prospective study. [Abstract] Arthritis Rheum 2003; 48 (Suppl. 9): S124.
16. Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 2002; 46: 1171-6.
17. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224-33.
18. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346: 1349-56.
19. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial. Lancet 2000; 356: 385-90.
20. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
21. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003; 49: S112-7.
22. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo clinic: The first 100 patients. Am J Gastroenterol 2001; 96: 722-9.
23. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistula in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
24. Sandbom WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120: 13308.
25. Sandbom WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94.
26. Travis SPL, Czajkowski M, McGovern DPB, et al. Treatment of intestinal Behçet's syndrome with chimeric tumor necrosis factor α antibody (infliximab). Gut 2001; 49: 725-8.
27. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001; 358: 295-6.
28. Morris DS, Gavin MP, Sturrock RD. The effect of anti-tumor necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease. Adv Exp Med Biol 2003; 528: 557-9.
29. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44: 1149-54.
30. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 2002; 41: 1303-7.
31. Gause AM, Arbach O, Reinhold-Keller E, et al. Induction of remission with infliximab in active generalized Wegener' Granulomatosis is effective but complicated by severe infection. [Abstract] Arthritis Rheum 2003; 48 (Suppl. 9): S450.
32. Baughman RP, Iannuzzi M. Tumor necrosis factor in sarcoidosis and its potential for targeted therapy. Biodrugs 2003; 17: 425-31.
33. Stokes DG, Kremer JM. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Sem Arthritis Rheum 2003; 33: 1-18.
34. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-4.
35. Rankin EC, Choy EGH, Kassimos D, et al. The therapeutic effects of an enginnered human anti-tumor necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334-42.
36. Davis MW, Feige U, Bendele AM, et al. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumor necrosis factor receptor type I: A clinical update. Ann Rheum Dis 2000; 59 (Suppl. 1): 141-3.
37. Black R, Rauch C, Kozlosky C, et al. A metalloproteinase disintegrin that releases TNF-α from cells. Nature 1997; 385: 729-36.
38. Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses TNF-α production by mononuclear cells. Int J Immunopharmacol 1993; 15: 409-13.
39. Seckinger P, Lowenthal JW, Williamson K, Dayer JM, Mac-Donald HR. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J immunol 1987; 139: 1546-9.
40. Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 2003; 42 (Suppl. 2): ii3-10.
41. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 927-34.
42. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with Anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-24.
43. Fehniger T.A, Caligiuri MA. Interleukin-15: Biology and Relevance to Human Disease. Blood 2001; 97: 14-32.
44. Ruchatz H, Leung BP, Wei XQ, et al. Soluble IL-15 Receptor Alpha-Chain Administration Prevents Murine Collagen-Induced Arthritis: A Role for IL-15 in Development of Antigen-Induced Immunopathology. J Immunol 1998; 160: 5654-60.
45. Kim Y, Maslinski W, Zheng XX, et al. Targeting the IL-15 Receptor with an Antagonist IL15/Fc Protein Blocks Delayed Type Hypersensitivity. J Immunol 1988; 160: 5742-8.
46. Villadsen LS, Schuurman J, Beurskens F, et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2203; 112: 1571-80.
47. Ferrari-Lacraz S, Zheng XX, Kim YS, et al. An Antagonist IL-15/Fc Protein Prevents Costimulation Blockade-Resistant Rejection. J Immunol 2001; 167: 3478-85.
48. Baslund B, Tvede N, Danneskiold-Samsoe B, et al. A novel human monoclonal antibody against IL-15 (HuMax-IL-15) in patients with active Rheumatoid arthritis: Results of a double-blind placebo-controlled phase I/II trial. [Abstract] Arthritis Rheum 2003; 48 (Suppl. 9): S1706.
49. Dinarello CA. Setting the cytokine trap for autoimmunity. Nature Med 2003; 9: 20-2.
50. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: Multi-component, high-affinity blockers of cytokine action. Nature Med 2003; 9: 47-52.
51. Moreland L, Gugliotti R, King K, et al. Results of a phase I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-II (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res 2001; 3: 247-52.
52. Asadullah K, Docke WD, Ebeling M, et al. Interleukin 10 treatment of psoriasis: Clinical results of a Phase II trial. Arch Dermatol 1999; 135: 187-92.
53. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43: 662-7.
54. Li DK, Zhao GJ, Paty DW. Randomised controlled trial of interferon-beta-1a in secondary progressive MS: MR1 results. Neurology 2001; 56: 1505-13.
55. Davis JC, Jr, Totoritis MC, Rosenberg J, et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 95-101.
56. Grammer AC, Slota R, Fischer R, et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003; 112: 1506-20.
57. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 303: 3243-52.
58. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T. cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-15.
59. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 2003; 148: 784-8.
60. Lebwohl M. Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349: 2004-13.
61. Gauvreau GM, Becker AB, Boulet LP, et al at. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airwayresponses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003; 112: 331-8.
62. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32.
63. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
64. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders. Prospects for antoimmune cell therapy. Arthritis Rheum 2003; 48: 1484-92.
65. Krause I, Valesini G, Scrivo R, Shoenfeld Y. Autoimmune aspects of cytokine and anticytokine therapies. Am J Med 2003; 115: 390-7.
66. Yazici Y, Erkan D, Paget SA. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum 2003; 48: 2769-72.
67. McInnes IB, Liew FY. Interleukin 15: A proinflammatory role in rheumatoid arthritis synovitis. Immunol Today 1998; 19: 75-9.
68. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.